The US Food and Drug Administration (FDA) has approved a labeling update for the injectable LDL-lowering agent inclisiran (Leqvio) that expands its indications to include primary prevention for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback